Mr. Hartman discusses advantages over existing antibodies.

Jackson Center, PA, November 16, 2020Halberd Corporation (OTC-PINK: “HALB“) Chairman, President and CEO, William A. Hartman, was interviewed recently by host, Donald Baillargeon, on Money TV. In the segment, Mr. Hartman provided information on Halberd’s new patent pending Covid-19 fluorescent antibody.  This should allow for rapid detection of the virus in infected patients and provide up-to-the-minute status of whether or not an individual has contracted the virus.

This should be much more helpful in preventing the spread of the virus than “Covid-19 Passports” which only represent the recent past condition of the passport holder.  This passport is in use in the UK and is being considered for use elsewhere.  Halberd’s quick test could prove to be a boon to the travel and entertainment industry in screening entrants to airports, train stations, sporting events and large gatherings to determine up to the minute status of the presence of Covid-19 antigens.  Development is continuing on the Halberd system to improve the accuracy of results by eliminating false positive or false negative results experienced with competitive tests currently in use.

Hartman added that this fluorescent antibody could not only be used in a diagnostic capacity, but just as with Halberd’s initial antibody, could be used as both a preventative measure in a nasal spray delivery context, or as a therapeutic for patients who have contracted the disease.  Work is continuing on Halberd’s nasal spray preventative against Covid-19 as an alternative to a vaccine.

Hartman alluded to additional new Halberd developments on which a provisional patent has been filed with details to be disclosed soon.

You can view the entire interview video here.

If you would like to be added to our email subscriber list, click here and submit the form.

For more information please contact:
William A. Hartman
P. O. Box 25
Jackson Center, PA 16133

About Halberd Corporation.
Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” and, “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” and “Nasal Spray to Prevent the Transmission of Covid-19.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.


Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.